Abstract:INTRODUCTION: Diabetic retinopathy is a serious public health concern. Vision impairment follows from intraocular vascular proliferation known as proliferative diabetic retinopathy (PDR) and/or from diabetic macular edema (DME). Clinical acumen and a recent meta-analysis of published studies suggest that the presence of a posterior vitreous detachment (PVD) reduces the risk of developing PDR, and has a favourable impact on DME. Pharmacologic vitreolysis by ocriplasmin or other agents may provide a minimally invasive method of achieving a PVD. If demonstrated in appropriate clinical studies including randomized trials, it would provide an interesting approach to prevent advanced and blinding stages of diabetic retinopathy, particularly in areas where access to care is limited.AREAS COVERED: The current epidemiology of diabetic retinopathy is reviewed as well as the role of the vitreous and its separation from the retina known as a PVD in DR based on a recent meta-analysis of published literature regarding the contribution of complete, partial or absent PVD to PDR and DME. The principles underlying vitreolysis and the induction of PVD are reviewed as well as the challenges faced by a pharmacologic approach. The results of clinical trials on the use of ocriplasmin are analyzed regarding its possible use in DR.EXPERT OPINION: Ocriplasmin has the ability to liquefy the vitreous and induce a PVD in a statistically significant number of patients. However, current studies on patients with vitreomacular adhesion and traction suggest that the majority of patients would not achieve a PVD with a single injection. As shown in the meta-analysis, a complete PVD is required to significantly reduce the risk of PDR, while a partial PVD may worsen the prognosis. If a strategy can be developed that insures a complete PVD within an appropriate time interval, the prevention of PDR might become a realistic target for ocriplasmin or other vitreolytic agents. In DME, release of traction whether complete or partial is associated with a reduction in DME, which in several cases has resulted in improved vision. While no studies have been conducted on the use of ocriplasmin or other vitreolytic agents in DR, a few studies using plasmin indicate that it is likely to have a beneficial effect in DME. Based on the information available, randomized clinical trials would be required to evaluate the clinical relevance of ocriplasmin and other potential vitreolytic agents in both forms of DR. Such trials could determine the efficacy of this strategy as compared to prophylatic laser particularly in high-risk populations. New follow-up and treatment strategies would also be required should initial studies be encouraging.

[Pharmacologic Vitreolysis in Diabetic Rats].

PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy.

The Effect Mechanism of Pharmacological Vitreolysis with Plasmin and Hyaluronidase

Posterior Vitreous Detachment with Plasmin in the Isolated Human Eye

Plasmin and dispase in inducing posterior vitreous detachment in rabbit eyes

Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator

Enzyme-induced Vitreolysis Can Alleviate the Progression of Diabetic Retinopathy Through the HIF-1α Pathway.

Ultrastructure Research of Posterior Vitreous Detachment

Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis.

An experimental study on dispase inducing posterior vitreous detachment

Efficacy and safety of t-PA in inducing experimental posterior vitreous detachment

Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator.

Posterior Vitreous Detachment Induced by Intravitreal Injection of Lysine-Plasminogen and Reteplase in Rabbits

Production of recombinant human microplasminogen and pilot study in inducing posterior vitreous detachment.

Experimental Study of Posterior Vitreous Detachment with Plasmin in Human Eyes

Experimental Induction of Posterior Vitreous Detachment in Rabbits with Hyaluronidase and Perfluoroethane (C2F6)

A pilot study on purification of human plasminogen from cord blood plasma and inducing posterior vitreous detachment

A novel recombinant human microplasminogen induced complete posterior vitreous detachment without morphological change of retina in juvenile rabbits

Effect of Intravitreal Injection of Ranibizumab on Retinal Ganglion Cells and Microvessels in the Early Stage of Diabetic Retinopathy in Rats with Streptozotocin-Induced Diabetes

Ocriplasmin for diabetic retinopathy

Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes.